- The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart ...

Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) significantly reduces the risk of cardiovascular death or hospitalization ...

A statement from the makers of the SGLT2 inhibitor empagliflozin suggests the benefits in heart failure with preserved ejection fraction (HFpEF) are significant. For the first time, a clinical trial ...

- In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint ...

(UPDATED) Full results of the EMPEROR-Preserved trial affirm that empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) lowers the risk of CV death/hospitalization for heart failure in patients ...

The lack of approved treatments for heart failure with preserved ejection fraction has represented a significant unmet need for a condition that affects 50% of patients with heart failure, including ...

Chronic kidney disease (CKD) had no impact on the efficacy or safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) for patients with heart ...

Patients with heart failure with preserved ejection fraction (HFpEF) -- a notoriously difficult population to treat -- had a meaningful reduction in cardiovascular death and heart failure ...

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...

Please provide your email address to receive an email when new articles are posted on . In patients with HF with preserved ejection fraction, empagliflozin reduced risk for serious hospitalizations ...

The EMPEROR-Preserved trial of empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) met its primary endpoint, according to top-line results released today, meaning a therapy with specific ...

Please provide your email address to receive an email when new articles are posted on . Empagliflozin reduced CV death or HF hospitalization compared with placebo in patients with HF with preserved ...